Syneos Health and Haystack Health have announced a strategic collaboration to improve patient identification and enrolment for clinical trials.
The partnership also aims to expedite clinical trials with artificial intelligence (AI) and will deliver valuable research tools and workflow efficiencies for sponsors and sites.
Go deeper with GlobalData
These tools result in improved timelines, along with increased recruitment of patients.
The new data solutions will be initially available only for Syneos US sites, with a focus on immunology and oncology. Later this year, they are planned to be expanded to include more therapeutic areas and global sites.
The combined capabilities of Syneos and Haystack will help enhance trial lifecycles for patients, sites, and sponsors, and improve strategies for recruitment to focus on those who are less likely to fail trial screeners.
See Also:
This minimises the burden on patients, trials, and sites.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSyneos Health Technology and Data Solutions president Baba Shetty said: “The challenges of enrolling patients in clinical trials are well documented. Protocol complexity and specificity in precision medicine have made patient recruitment even more difficult.
“Haystack Health offers an advanced solution leveraging AI to match patients to trials while preserving privacy.”
Over several months, Syneos and Haystack have been working with sites and sponsors directly and could identify eligible patients for specific trials in near-real time.
This aided in rapid patient engagement and accelerated enrolment for hard-to-enroll trials in areas such as complex auto-immune conditions, advanced cancers, and progressive diseases, among others.
Haystack Health CEO Steve Whitehurst said: “For overburdened and busy research sites, additional time spent on screening patients who never actually enroll into a trial could have been much more effectively spent on patient care.
“Clearly, better pre-screening methodologies are urgently needed to reduce screen failure rates, enabling faster clinical development and improved patient care.”
In September 2021, Syneos acquired technology-enabled clinical trial recruitment and retention company, StudyKIK, to enhance its ability to offer technology and insight-driven solutions.
